Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LIG1 | P18858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22071237 | 0.82 | DAO (0.52) | DAOPKMLIG1RAB9AHDAC8 | |
| SCHEMBL10638684 | 0.81 | S1PR1 (0.41) | DAORAB9AHDAC8MEN1KMT2A | |
| SCHEMBL352339 | 0.81 | L3MBTL1 (0.56) | DAORAB9AHDAC8S1PR2S1PR4 | |
| SCHEMBL7205892 | 0.81 | F2 (0.52) | DAORAB9AHDAC8S1PR2S1PR4 | |
| SCHEMBL2226439 | 0.80 | NPSR1 (0.51) | HDAC8MEN1POLBKMT2AS1PR2 | |
| SCHEMBL5162659 | 0.80 | DAO (0.50) | DAOPKMLIG1RAB9AHDAC8 | |
| SCHEMBL8739630 | 0.79 | ALDH1A1 (0.59) | RAB9AMEN1POLBKMT2AALDH1A1 | |
| SCHEMBL1277482 | 0.78 | HDAC8 (0.66) | DAOPKMLIG1RAB9AHDAC8 | |
| SCHEMBL29808747 | 0.78 | DAO (0.64) | DAOPKMLIG1RAB9AMEN1 | |
| SCHEMBL6284311 | 0.76 | GSK3B (0.56) | HDAC8MEN1KMT2AS1PR2S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604326-B1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORP (JP) | 2026-01-07 | — | — | EP | disclosed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| CN-118248927-A | High-temperature-resistant long-service-life lithium ion or sodium ion battery and preparation method thereof | 深圳市固易能科技有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024086804-A1 | INDOLIZINE DERIVATIVES FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3687543-B1 | COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20020072626-A1 | Methods for producing 3-cyano- and 4-cyano-benzoic acid derivative compounds | COR THERAPEUTICS, INC. | 2002-06-13 | — | — | US | disclosed |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2002015662-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016355-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC) ACETYLCHOLINE RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002017358-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2001042198-A2 | METHODS FOR PRODUCING CYANOBENZOIC ACID DERIVATIVES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| US-5344834-A | Functionalized vinyl azoles and methods of use | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-09-06 | — | — | US | disclosed |
| EP-0550697-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING FUNCTIONALIZED VINYLAZOLES, USE OF THESE VINYLAZOLES FOR PRODUCING MEDICAMENTS, THESE VINYLAZOLES THEMSELVES AND PROCESS FOR PRODUCING THE SAME | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992010482-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING FUNCTIONALIZED VINYLAZOLES, USE OF THESE VINYLAZOLES FOR PRODUCING MEDICAMENTS, THESE VINYLAZOLES THEMSELVES AND PROCESS FOR PRODUCING THE SAME | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072626-A1 | Methods for producing 3-cyano- and 4-cyano-benzoic acid derivative compounds | PFKP, PCCA, TBXAS1 | DAO 122/4885PKM 1978/4885LIG1 267/4885 |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | DAO 2453/4885PKM 625/4885LIG1 4862/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | DAO 2453/4885PKM 625/4885LIG1 4862/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | DAO 2453/4885PKM 625/4885LIG1 4862/4885 |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | DAO 1360/4885PKM 2752/4885LIG1 1813/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | DAO 4312/4885PKM 3237/4885LIG1 4854/4885 |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PARK7, CYP3A7, UGT2B7 | DAO 1098/4885PKM 4026/4885LIG1 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.